Open-house model for pharmaceutical discount agreements for raloxifene, ATC G03XC01

Summary

This is an open-house model for non-exclusive pharmaceutical discount agreements concerning raloxifene (ATC G03XC01), rather than a competitive open procedure. AOK Bayern intends to conclude identical, non-negotiable agreements with every interested pharmaceutical company that meets the stated requirements. The earliest contract start is 1 November 2026, contracts end on 31 October 2028, and participation is possible until 3 September 2028. Complete and correctly signed documents received by the third day of a month generally lead to a contract start on the following month’s first day. The submission route and signature requirements must be followed carefully.